Tranexamic Acid Shows Efficacy Across All Three Routes for Melasma
Melasma and hyperpigmentation rank among the most persistent skin concerns for women in their twenties through forties. Hydroquinone, long the standard treatment, carries well-documented risks: skin irritation, contact dermatitis, and rebound darkening with prolonged use. A 2026 systematic review published in the Journal of Cosmetic Dermatology now consolidates the evidence for tranexamic acid (TXA) across all three delivery routes.
The review’s central finding: oral, topical, and intradermal TXA all produce meaningful pigmentation improvement. The magnitude and durability of results differ by route, but no single method was without clinical benefit.
How it works: a pathway blocker, not a bleach
Tranexamic acid does not destroy melanin or bleach the skin. Its mechanism operates further upstream. TXA inhibits plasmin, an enzyme that participates in the signaling pathway through which keratinocytes (surface skin cells) stimulate melanocytes (pigment-producing cells).
UV exposure, hormonal shifts, and inflammation all amplify this keratinocyte-to-melanocyte signal, driving excess melanin production. TXA cuts that signal before it reaches the melanocyte, reducing pigmentation output without directly targeting melanin itself.
Oral TXA: strongest MASI score reduction
Measured by MASI (Melasma Area and Severity Index), oral tranexamic acid produced the most substantial score decreases across the three routes. The most commonly studied protocol is 250~500mg twice daily. Side effects are generally mild, including nausea and GI discomfort, with some patients reporting menstrual cycle irregularities. Retrospective case series have followed oral TXA use for more than six months, but robust long-term safety data from large trials is still accumulating.
Topical and intradermal: hydroquinone parity with fewer reactions
Topical TXA formulations (creams, serums) and intradermal microinjections both demonstrated results comparable or superior to hydroquinone in head-to-head studies. The critical difference is tolerability. Hydroquinone’s known risk profile, including irritant reactions and post-inflammatory rebound, was significantly reduced with TXA formulations.
Intradermal delivery reaches deeper dermal pigmentation more directly than surface application, and several studies reported faster improvement timelines compared to topical-only regimens.
Combination therapy: enhanced and longer-lasting outcomes
The review highlighted combination approaches as particularly promising. When TXA was paired with hydroquinone or laser treatment, both the magnitude of improvement and the duration of results exceeded what either treatment achieved alone.
The mechanism logic is complementary: TXA blocks upstream stimulation, hydroquinone inhibits melanin synthesis, and laser clears existing deposited pigment. Stacking these three distinct pathways addresses the pigmentation cycle more comprehensively and reduces the risk of recurrence.
Beyond melasma: post-inflammatory hyperpigmentation
Evidence for TXA in post-inflammatory hyperpigmentation (PIH), the brown marks that follow acne or procedures, is growing, though the literature base is smaller than for melasma. Since PIH also involves plasmin-mediated melanocyte stimulation following inflammation, TXA’s pathway-blocking mechanism is theoretically well-suited to this indication as well.
Frequently Asked Questions
What was tranexamic acid originally developed for? Tranexamic acid was developed as a hemostatic agent that inhibits fibrin breakdown during blood clotting. It was used to reduce surgical bleeding and treat heavy menstrual periods. Its pigmentation-suppressing effect was discovered as a secondary observation, which eventually led to dermatological applications.
How does tranexamic acid compare to hydroquinone for melasma? Hydroquinone directly inhibits tyrosinase, the enzyme that produces melanin. Tranexamic acid works upstream by blocking plasmin, which reduces the signal that activates melanocytes. TXA shows comparable or superior results in several studies, with significantly fewer irritant reactions and lower risk of rebound hyperpigmentation associated with long-term hydroquinone use.
What should I know before taking oral tranexamic acid? The most studied oral dose is 250 to 500mg twice daily (BID). Reported side effects include mild gastrointestinal symptoms and, in some cases, menstrual cycle changes. Long-term safety data beyond six months is still limited in large-scale studies, so consultation with a physician before use is recommended.